A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Inclusion Criteria:

• Have Type 2 Diabetes Mellitus (T2DM) for ≥1 year prior to screening

• Treated for ≥90 days prior to screening with multiple daily injection (MDI) therapy

• on basal insulin or insulin glargine 100 U/mL [Basaglar or Lantus] or insulinglargin 300 U/mL, insulin determir, insulin degludec U-100, or neutralprotamine Hagedorn (NPH) insulin) in combination with at least 1 prandialinjection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulinaspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or

• premixed analog or human insulin regimens with any basal and bolus insulin

• May have been treated with up to 3 oral antihyperglycemic medications (OAMs)including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordancewith local regulations. The dose of all OAMs must have been stable for ≥90 daysprior to screening

• Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening

• Body mass index ≤45.0 kg/m²

• Have access to a telephone, or alternative means for close monitoring/communications

• Have refrigeration at home or have ready access to refrigeration for storage ofinsulin therapy

• Have a regular wake-sleep schedule (awake-work during the day and sleep during thenight)

Exclusion Criteria:

• Having any other condition (including known drug or alcohol abuse, psychiatricdisorder including eating disorder) that precludes the subject from following andcompleting the protocol

• Have been diagnosed, at any time, with type 1 diabetes mellitus (T1DM) or latentautoimmune diabetes in adults

• Have hypoglycemia unawareness as judged by the investigator

• Have had any episode of severe hypoglycemia (defined as requiring assistance due toneurologically disabling hypoglycemia) within the 6 months prior to screening

• Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolarstate within the 6 months prior to screening

• Have a known diagnosis of secondary diabetes (for example, diabetes caused byhemochromatosis, acromegaly, chronic pancreatitis, or pancreatectomy)

• Excessive insulin resistance defined as having received a total daily dose ofinsulin >2.0 U/kg at the time of screening

• Have a history of or are being evaluated for bariatric surgery including Roux-en-Ygastric bypass surgery, gastric banding, and/or gastric sleeve

• Have cardiovascular disease, within the past 6 months prior to screening, defined asstroke, decompensated heart failure (New York Heart Association Class III or IV),myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft

• History of renal transplantation

• Currently receiving renal dialysis

• Serum creatinine >2.0 mg/dL (177 µmol/L) at screening

• Have obvious clinical signs or symptoms of liver disease (for example, acute orchronic hepatitis or cirrhosis), or elevated liver enzyme measurements

• Have active or untreated malignancy, have been in remission from clinicallysignificant malignancy (other than basal cell or squamous cell skin cancer) for lessthan 5 years, or are at an increased risk for developing cancer or a recurrence ofcancer in the opinion of the investigator

• Have had a blood transfusion or severe blood loss within 90 days prior to screeningor have known hemoglobinopathy, anemia, or any other traits known to interfere withmeasurement of HbA1

• Have presence of clinically significant gastrointestinal disease (for example,clinically active gastroparesis associated with wide glucose fluctuations) in theinvestigator's opinion

• Have used thiazolidinediones, glucagon-like peptide 1 receptor agonist, orpramlintide within 90 days prior to screening